News Trump disbands business forums as CEOs quit J&J's CEO Gorsky also quit before Trump axed councils
News Janssen/AbbVie drug approved in graft-versus-host disease First use for Imbruvica outside blood cancer.
News FDA advisers reject J&J rheumatoid arthritis drug Expert panel concerned about safety of sirukumab.
Views & Analysis A radical re-thinking of healthcare – J&J’s push for ‘immorb... J&J: don’t just treat disease, prevent it and intercept it.
News J&J's psoriasis drug faces crowded market after US approval J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.
News Novartis' psoriasis drug gets label boost New label shows Cosentyx is superior to J&J's rival in long-term.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.